| Bioactivity | Sulindac (MK-231) is an orally active nonsteroidal anti-inflammatory agent. Sulindac also is an immunomodulatory agent. Sulindac can be used for the research of arthritis of the spine, gouty arthritis and kinds of cancer including colorectal cancer (CRC) and lung cancer[1][2]. |
| Invitro | Sulindac (MK-231) (500 μM, 48 h) sodium is effective in preventing TGF-β1-induced EMT, as indicated by upregulation of the epithelial marker, E-cadherin, and downregulation of mesenchymal markers and transcription factors[1]. Sulindac sodium (500 μM, 48 h) can inhibit TGF-β1-enhanced migration and invasion of A549 cells[1]. Sulindac sodium (500 μM, 48 h) enhances the reversal of TGF-β1-induced EMT by sulindac (sodium) and SIRT1 upregulation promoted TGF-β1-induced EMT[1]. Western Blot Analysis[1] Cell Line: |
| In Vivo | Sulindac (MK-231) sodium (15 mg/kg, p.o., bid (sulindac alone); 7.5 mg/kg p.o., bid (sulindac combination with PD-L1)) shows a significant reduction in tumor volume and increases infiltration of CD8+ T lymphocytes in the tumor tissues when treated with combination therapy[2]. Sulindac sodium (15 mg/kg, p.o., bid (sulindac alone); 7.5 mg/kg p.o., bid (sulindac combination with PD-L1)) can downregulate PD-L1 by blocking NF-κB signaling, which in turn led to a decrease in exosomal P[2]. Sulindac sodium (15 mg/kg, p.o., bid (sulindac alone); 7.5 mg/kg p.o., bid (sulindac combination with PD-L1)) leads to increased availability of PD-L1 Ab by downregulating PD-L1 in combination therapy[2]. Sulindac sodium has not a systemic inhibitory effect on prostaglandin E2 (PGE2) in low-dose does[2]. Animal Model: |
| Name | Sulindac sodium |
| CAS | 63804-15-9 |
| Formula | C20H16FNaO3S |
| Molar Mass | 378.39 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Byong-Ki Cha, et al. Celecoxib and sulindac inhibit TGF-β1-induced epithelial-mesenchymal transition and suppress lung cancer migration and invasion via downregulation of sirtuin 1. Oncotarget. 2016 Aug 30;7(35):57213-57227. [2]. Bin Yi, et al. Sulindac Modulates the Response of Proficient MMR Colorectal Cancer to Anti-PD-L1 Immunotherapy. Mol Cancer Ther. 2021 Jul;20(7):1295-1304. |
Sulindac sodium
CAS: 63804-15-9 F: C20H16FNaO3S W: 378.39
Sulindac (MK-231) is an orally active nonsteroidal anti-inflammatory agent. Sulindac also is an immunomodulatory agent.
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.